← All trials
NCT05948475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Jul 17, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 200
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TransThera Biosciences Co., LtdLead sponsor
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.